📊 TMCI Key Takeaways
Is Treace Medical Concepts, Inc.. (TMCI) a Good Investment?
Treace Medical faces a profitability crisis with severe operating losses (-36.4% margin) despite strong gross margins (79.3%), indicating underlying operational inefficiency. Revenue growth is essentially flat (1.6% YoY) leaving no clear path to profitability, while the company carries $55.8M in debt with negative interest coverage and only $9.5M in cash.
Treace Medical Concepts, Inc.. Key Strengths (TMCI)
- Exceptional gross margin of 79.3% indicates strong core product economics and pricing power
- Positive free cash flow of $4.2M despite operating losses provides near-term runway
- Solid short-term liquidity with current ratio of 3.58x
TMCI Stock Risks: Treace Medical Concepts, Inc.. Investment Risks
- Severe profitability crisis with -$17.2M operating loss and -38.1% net margin showing unsustainable operational structure
- Stagnant revenue growth of 1.6% YoY provides no near-term path to profitability or earnings improvement
- High debt burden of $55.8M with negative interest coverage ratio (-10.9x) creates financial distress risk and limits strategic flexibility
- Depleting cash position relative to debt obligations and operating burn rate
Key Metrics to Watch
- Operating margin trajectory and operating expense reduction initiatives
- Revenue growth acceleration and market share trends in surgical device segment
- Cash balance depletion rate and debt covenant compliance status
- Operating cash flow sustainability given negative net income
Treace Medical Concepts, Inc.. (TMCI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.58x current ratio provides a solid financial cushion.
TMCI Profit Margin, ROE & Profitability Analysis
TMCI vs Healthcare Sector: How Treace Medical Concepts, Inc.. Compares
How Treace Medical Concepts, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Treace Medical Concepts, Inc.. Stock Overvalued? TMCI Valuation Analysis 2026
Based on fundamental analysis, Treace Medical Concepts, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Treace Medical Concepts, Inc.. Balance Sheet: TMCI Debt, Cash & Liquidity
TMCI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Treace Medical Concepts, Inc..'s revenue has grown significantly by 125% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.81 indicates the company is currently unprofitable.
TMCI Revenue Growth, EPS Growth & YoY Performance
TMCI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $47.2M | -$15.9M | $-0.25 |
| Q3 2025 | $45.1M | -$15.4M | $-0.25 |
| Q2 2025 | $44.5M | -$15.9M | $-0.28 |
| Q1 2025 | $51.1M | -$15.9M | $-0.25 |
| Q3 2024 | $40.8M | -$12.3M | $-0.25 |
| Q2 2024 | $42.0M | -$12.3M | $-0.20 |
| Q1 2024 | $42.2M | -$13.5M | $-0.23 |
| Q3 2023 | $33.1M | -$9.0M | $-0.22 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Treace Medical Concepts, Inc.. Dividends, Buybacks & Capital Allocation
TMCI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Treace Medical Concepts, Inc.. (CIK: 0001630627)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TMCI
What is the AI rating for TMCI?
Treace Medical Concepts, Inc.. (TMCI) has an AI grade of C with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TMCI's key strengths?
Claude: Exceptional gross margin of 79.3% indicates strong core product economics and pricing power. Positive free cash flow of $4.2M despite operating losses provides near-term runway.
What are the risks of investing in TMCI?
Claude: Severe profitability crisis with -$17.2M operating loss and -38.1% net margin showing unsustainable operational structure. Stagnant revenue growth of 1.6% YoY provides no near-term path to profitability or earnings improvement.
What is TMCI's revenue and growth?
Treace Medical Concepts, Inc.. reported revenue of $47.2M.
Does TMCI pay dividends?
Treace Medical Concepts, Inc.. does not currently pay dividends.
Where can I find TMCI SEC filings?
Official SEC filings for Treace Medical Concepts, Inc.. (CIK: 0001630627) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TMCI's EPS?
Treace Medical Concepts, Inc.. has a diluted EPS of $-0.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is TMCI's fundamental grade?
Based on our AI fundamental analysis in June 2026, Treace Medical Concepts, Inc.. has a C grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is TMCI stock overvalued or undervalued?
Valuation metrics for TMCI: ROE of -23.3% (sector avg: 15%), net margin of -38.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is TMCI's AI grade for 2026?
Our dual AI analysis gives Treace Medical Concepts, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TMCI's free cash flow?
Treace Medical Concepts, Inc..'s operating cash flow is $7.2M, with capital expenditures of $3.1M. FCF margin is 8.9%.
How does TMCI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -38.1% (avg: 12%), ROE -23.3% (avg: 15%), current ratio 3.58 (avg: 2).